Erschienen in:
01.10.2012 | Letter
Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors
verfasst von:
A. J. Scheen
Erschienen in:
Diabetologia
|
Ausgabe 10/2012
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: The position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recently published an updated algorithm for the initiation and adjustment of therapy for the management of hyperglycaemia in type 2 diabetes [
1]. Interestingly, from a clinical point of view, the paper recommends a patient-centred strategy and gives some key properties for each medication to help physicians choose the best option for an individual patient. This personalised approach should take into account the efficacy and safety profile of the glucose-lowering compound, its cost and some clinical characteristics of the diabetic patient. In contrast to the previous version [
2] and taking into account previous criticism [
3], dipeptidyl peptidase IV (DPP-4) inhibitors (also called gliptins) [
4] are now considered a possible valuable alternative to other pharmacological options after failure to respond to metformin monotherapy. …
